NOV 17, 202662 MINS READ
Creatine phosphate serves as a rapid-response energy reservoir in high-demand tissues, particularly skeletal muscle, cardiac muscle, and brain. The creatine kinase (CK) enzyme catalyzes the reversible transfer of a phosphate group from CP to ADP, regenerating ATP during periods of intense metabolic activity 1. This phosphagen system is especially critical during the initial seconds of muscle contraction and neuronal firing, when ATP consumption exceeds mitochondrial production capacity 2. In vertebrate tissues, CP concentrations typically range from 20 to 35 mM in resting muscle and 5 to 10 mM in brain tissue, with rapid depletion (35–96%) observed during high-intensity exercise or ischemic episodes 11. The stoichiometric relationship between CP, ATP, ADP, and AMP forms the basis for all tissue analysis methodologies, as these metabolites exist in dynamic equilibrium governed by CK and adenylate kinase (AK) activities 2.
The molecular mechanism underlying CP function involves the high-energy phosphate bond (ΔG°' ≈ -43 kJ/mol), which enables efficient energy transfer under physiological pH (6.5–7.5) and magnesium ion concentrations (1–5 mM) 615. Tissue-specific isoforms of creatine kinase—including cytosolic CK-MM (muscle), CK-BB (brain), and mitochondrial CK (mt-CK)—exhibit distinct kinetic properties and subcellular localizations that optimize energy distribution 39. For example, mt-CK couples oxidative phosphorylation directly to CP synthesis, creating localized energy microdomains at the mitochondrial outer membrane 4. Understanding these biochemical principles is essential for interpreting tissue analysis data, as CP levels reflect not only total energy reserves but also the functional integrity of CK-mediated energy shuttling pathways.
Traditional enzymatic assays for CP quantification rely on coupled enzyme reactions that convert CP-derived ATP into spectroscopically detectable products 18. The standard reaction sequence involves: (1) CP + ADP → creatine + ATP (catalyzed by endogenous or exogenous CK); (2) ATP + glucose → glucose-6-phosphate + ADP (hexokinase-catalyzed); and (3) glucose-6-phosphate + NAD(P)⁺ → 6-phosphogluconate + NAD(P)H (glucose-6-phosphate dehydrogenase-catalyzed) 815. The rate of NAD(P)H formation, measured at 340 nm, is directly proportional to initial CP concentration. This approach achieves detection limits of approximately 0.1–1.0 µM in tissue extracts when optimized with appropriate buffer systems (pH 6.5–7.5), magnesium acetate (5–10 mM), and substrate concentrations (glucose 10 mM, ADP 2 mM) 15.
A critical advancement involves the use of sulfonic acid-based buffers (TES, TAPSO, MOPSO, MES) rather than traditional imidazole or Tris buffers, which significantly reduces spontaneous ATP formation during storage and improves assay stability 36. For instance, analytical elements employing TES buffer showed zero ATP formation after 1 day at 45°C/11% RH, compared to 27.15 nmol with imidazole buffer 3. Mathematical modeling of CP concentration from ATP measurements has been developed for brain tissue analysis, utilizing the equilibrium constant of the CK reaction (Keq ≈ 160) and measured ATP/ADP ratios to back-calculate CP levels under normoxic and hypoxic conditions 1. This indirect approach is particularly valuable when direct CP measurement is complicated by rapid enzymatic degradation during tissue processing.
LC-MS/MS has emerged as the gold standard for simultaneous quantification of CP, ATP, ADP, AMP, and creatine in tissue homogenates and whole organisms 2. The method employs reversed-phase chromatography with volatile mobile phases (typically ammonium acetate or formic acid buffers) and electrospray ionization in negative mode, detecting the characteristic mass transitions: CP (m/z 210 → 79), ATP (m/z 506 → 159), ADP (m/z 426 → 159), AMP (m/z 346 → 79), and creatine (m/z 132 → 90) 2. Sample preparation involves rapid tissue homogenization in ice-cold perchloric acid (0.6 M) or methanol/water mixtures to immediately halt enzymatic activity, followed by neutralization with potassium carbonate and centrifugation to remove precipitated proteins 2.
Key advantages of LC-MS/MS include: (1) elimination of enzyme-dependent variability; (2) resolution of all five energy metabolites in a single 10–15 minute run; (3) quantification ranges from 0.01 to 100 µM with linearity R² > 0.995; and (4) applicability to diverse sample types including muscle biopsies (5–10 mg), brain tissue sections (1–2 mm³), and even whole nematodes (C. elegans) 2. The method has been validated for precision (CV < 5% intra-day, < 10% inter-day) and recovery (95–105% for spiked standards) across multiple tissue matrices 2. For researchers investigating energy metabolism in small animal models or limited clinical samples, LC-MS/MS provides unparalleled sensitivity and specificity, enabling detection of subtle metabolic shifts associated with disease progression or therapeutic intervention.
Non-invasive ³¹P-MRS allows real-time monitoring of CP, ATP, and inorganic phosphate (Pi) in living tissues, providing dynamic insights into energy metabolism without tissue destruction 45. The technique exploits the distinct chemical shifts of phosphorus-containing metabolites: CP (δ ≈ 0 ppm), γ-ATP (δ ≈ -2.5 ppm), α-ATP (δ ≈ -7.5 ppm), β-ATP (δ ≈ -16 ppm), and Pi (δ ≈ 5 ppm, pH-dependent) 4. Quantification is achieved by integrating peak areas and normalizing to an internal standard or total phosphorus signal, with typical spatial resolution of 1–8 cm³ and temporal resolution of 1–5 minutes 4. Clinical applications include assessment of muscle bioenergetics in mitochondrial myopathies (where CP/ATP ratios are reduced by 30–50%) and monitoring of cardiac energy status during ischemia-reperfusion injury 4.
A breakthrough innovation is the application of CEST imaging to visualize creatine kinase activity in tumors by tracking the conversion of exogenously administered phosphocreatine to creatine 45. The method involves: (1) intravenous injection of phosphocreatine (up to several millimolar, well-tolerated in vivo); (2) application of radiofrequency saturation pulses at the creatine amide proton frequency (δ ≈ 1.8 ppm) for 1–3 seconds; and (3) detection of water signal reduction proportional to creatine concentration 5. Since malignant tumors overexpress CK (particularly the BB isoform) by 2- to 10-fold compared to normal tissue, the rate of phosphocreatine-to-creatine conversion serves as a biomarker of tumor malignancy and metabolic aggressiveness 45. Preclinical studies in breast, prostate, and brain tumor models have demonstrated 20–40% CEST contrast enhancement in high-grade tumors versus 5–10% in low-grade lesions, with spatial resolution approaching 1 mm³ at 7–9.4 Tesla field strengths 5. This approach holds promise for non-invasive tumor grading, treatment response monitoring, and surgical margin delineation.
Dry analytical elements (also termed "dry chemistry" slides or test strips) provide rapid, user-friendly platforms for CK and CK-MB isoenzyme quantification in clinical settings 3679. These multi-layered devices typically comprise: (1) a transparent polyester support; (2) a reagent layer containing CP (1–2 g/m²), ADP (0.05–0.16 g/m²), buffer (TES, TAPSO, or MOPSO at pH 6.5–7.5), magnesium acetate, and an indicator enzyme system (hexokinase, glucose-6-phosphate dehydrogenase, NAD⁺); and (3) optionally, a spreading layer to ensure uniform sample distribution 36. For CK-MB-specific assays, the reagent layer incorporates monoclonal or polyclonal antibodies that selectively inhibit the M-subunit of CK, allowing only the MB isoenzyme to catalyze CP phosphorylation 679.
Critical design parameters include: (1) CP coating coverage ≥ 0.5 g/m² (preferably 1–2 g/m²) to ensure substrate excess throughout the assay; (2) ADP concentration optimized to 0.05–0.1 g/m² to balance reaction rate and background signal; (3) buffer pKa matched to the optimal pH range (6.5–7.5) for CK activity while minimizing spontaneous ATP formation; and (4) incorporation of P¹,P⁵-di(adenosine-5')pentaphosphate (DAPP, ≥ 0.03 g/m²) and AMP (10:1 to 14:1 molar ratio with ADP) to suppress interference from adenylate kinase, particularly the liver AK-1 isoenzyme 916. The latter additives are crucial for accurate CK-MB determination in serum samples containing elevated liver enzymes, as AK can catalyze the reaction 2 ADP → ATP + AMP, generating spurious ATP signals independent of CK activity 9.
Performance characteristics of optimized dry elements include: linear response range 10–500 U/L for CK-MB; coefficient of variation < 5% at 100 U/L; and storage stability > 12 months at 2–8°C with < 10% activity loss 36. Comparative studies have shown excellent correlation (r > 0.95) between dry element results and reference wet chemistry methods, with the added advantages of 1–10 µL sample volume, 2–5 minute analysis time, and elimination of liquid reagent handling 39. These features make dry analytical elements particularly suitable for emergency department cardiac marker testing and point-of-care applications in resource-limited settings.
An alternative approach to optical detection employs electrochemical quantification of CP using 1-methoxy-5-methylphenazinium (MMP) as a redox mediator 14. In this system, creatinine (a CP degradation product) directly reduces MMP to its colorless leuco form under alkaline conditions (pH 6–7, maintained by phosphate buffer at 5–500 mM), without requiring enzymatic catalysis 14. The reduced MMP is then oxidized at a working electrode (typically glassy carbon or screen-printed carbon) held at +0.2 to +0.4 V versus Ag/AgCl, generating an anodic current proportional to creatinine (and by extension, CP) concentration 14. The method achieves detection limits of 0.1–1.0 mM creatinine in urine and tissue extracts, with linear response up to 50 mM 14.
Key advantages include: (1) elimination of enzyme-related variability and storage instability; (2) compatibility with miniaturized sensor formats (e.g., screen-printed electrodes with 3 mm diameter working areas); (3) rapid response time (< 30 seconds); and (4) insensitivity to optical interferents (hemolysis, lipemia, bilirubin) that plague photometric assays 14. However, the method requires careful control of phosphate concentration, as reaction kinetics accelerate with increasing phosphate levels (optimal 5–1000 mM), and the presence of monovalent anions (chloride, nitrate, methylsulfate) is necessary to stabilize MMP in phosphate-containing media 14. This electrochemical approach is particularly well-suited for integration into wearable biosensors or implantable devices for continuous metabolic monitoring.
CP quantification in brain tissue provides critical insights into neuronal energy status during ischemic stroke, traumatic brain injury, and neurodegenerative diseases 1. Studies using the mathematical modeling approach described in 1 have demonstrated that CP levels in rat brain cortex decline from baseline values of 3.5–4.0 µmol/g wet weight to < 0.5 µmol/g within 5 minutes of complete ischemia, while ATP decreases from 2.5 µmol/g to 0.3 µmol/g over the same period 1. The CP/ATP ratio, normally maintained at approximately 1.4–1.6 in healthy brain, drops to < 0.5 during severe energy failure, serving as a sensitive indicator of impending neuronal death 1. Importantly, the method allows retrospective calculation of CP from ATP measurements in archived tissue samples, enabling re-analysis of historical studies without requiring fresh tissue collection 1.
Clinical translation of brain CP analysis has been achieved through ³¹P-MRS, which non-invasively measures CP and ATP in stroke patients during the acute phase (< 24 hours) and recovery period (1–4 weeks) 4. Patients with poor neurological outcomes show persistently low CP/ATP ratios (< 0.8) in peri-infarct regions, whereas those with good recovery exhibit normalization to > 1.2 within 7–14 days 4. These findings suggest that CP/ATP ratio could serve as a prognostic biomarker for stroke recovery and a pharmacodynamic endpoint for neuroprotective drug trials. Future research directions include development of CP-sensitive CEST contrast agents for high-resolution mapping of energy metabolism in specific brain nuclei and integration of CP measurements with other metabolic markers (lactate, N-acetylaspartate) to create comprehensive neuroenergetic profiles.
In skeletal muscle, CP analysis has been instrumental in understanding the bioenergetics of high-intensity exercise, fatigue mechanisms, and training adaptations 11. LC-MS/MS studies in human vastus lateralis biopsies have shown that CP content decreases from resting values of 80–90 mmol/kg dry weight to 20–40 mmol/kg after 30 seconds of maximal cycling, with concomitant increases in creatine, ADP, and AMP 211. The rate of CP resynthesis during recovery (typically 50% restoration in 30–60 seconds, complete recovery in 3–5 minutes) is limited by mitochondrial ATP production capacity and serves as a functional measure of oxidative metabolism 11. Athletes with higher aerobic fitness demonstrate faster CP recovery kinetics (t₁/₂ < 30 seconds) compared to sedentary individuals (t₁/₂ > 60 seconds), reflecting enhanced mitochondrial density and function 11.
Nutritional interventions targeting the CP system have been extensively studied using tissue analysis methods 11. Creatine supplementation (20 g/day loading for 5–7 days, followed by 3–5 g/day maintenance) increases muscle CP content by 10–30%, with corresponding improvements in repeated
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| GOSUDARSTVENNOE OBRAZOVATEL'NOE UCHREZHDENIE VYSSHEGO PROFESSIONAL'NOGO OBRAZOVANIJA "NIZHEGORODSKAJA GOSUDARSTVENNAJA MEDITSINSKAJA AKADEMIJA" | Neuroenergetics research, brain ischemia assessment, and circulatory hypoxia studies in experimental animal models. | Mathematical Modeling Method for Brain CP Determination | Enables retrospective calculation of creatine phosphate from ATP measurements in brain tissue under normoxic and hypoxic conditions, eliminating need for fresh tissue collection. |
| Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | Energy metabolism monitoring in muscle tissue biopsies, whole organism studies, and small animal models for metabolic disease research. | LC-MS/MS Multi-Analyte Detection System | Simultaneous quantification of ATP, ADP, AMP, CP, and creatine in tissue and nematodes with detection limits of 0.01-100 µM, linearity R²>0.995, and precision CV<5% intra-day. |
| Fuji Photo Film Co. Ltd. | Point-of-care cardiac marker testing in emergency departments, clinical diagnostics for myocardial infarction, and resource-limited healthcare settings. | Dry Analytical Element for CK-MB Detection | Utilizes sulfonic acid buffer (TES/TAPSO/MOPSO) achieving zero ATP formation after 1 day at 45°C/11%RH, linear response 10-500 U/L, CV<5%, and 12-month storage stability. |
| Sidra Medical and Research Center | Cancer malignancy assessment, tumor grading, treatment response monitoring, and surgical margin delineation in breast, prostate, and brain tumors. | CEST Imaging for Tumor CK Activity | Non-invasive visualization of creatine kinase activity in tumors showing 20-40% CEST contrast enhancement in high-grade tumors versus 5-10% in low-grade lesions at spatial resolution approaching 1 mm³. |
| Panasonic Corp. | Miniaturized biosensors, wearable metabolic monitoring devices, and point-of-care urinalysis in clinical and home healthcare applications. | Electrochemical Creatinine Detection Device | Employs 1-methoxy-5-methylphenazinium mediator for creatinine quantification with detection limits 0.1-1.0 mM, response time <30 seconds, and insensitivity to optical interferents. |